Mirum Pharmaceuticals

Patent cliffs & loss of exclusivity

Mirum Pharmaceuticals develops and commercializes medicines for rare diseases, including rare liver and genetic disorders. Its approved portfolio includes LIVMARLI, CHOLBAM, CTEXLI and ATEBRIOZ, alongside investigational programs for cholestatic liver diseases, hepatitis delta and Fragile X syndrome. Founded in 2018, the company is headquartered in Foster City, California.

Company

Legal NameMirum Pharmaceuticals, Inc.
Company Operating StatusActive
Crunchbase URLhttps://www.crunchbase.com/organization/mirum-pharmaceuticals
Email format{f}{last}
Facebook URLhttps://www.facebook.com/mirumpharma/
Full Address950 Tower Lane, Suite 1050, Foster City, CA 94404, US
Instagram URLhttps://www.instagram.com/mirumpharma/
LinkedIn URLhttps://www.linkedin.com/company/mirum-pharmaceuticals

7 upcoming patent cliffs

DrugIngredientTypeCliff
  1. CTEXLICHENODIOLSmall mol.Feb 2032
  2. LIVMARLIMARALIXIBAT CHLORIDESmall mol.Oct 2032
  3. LIVMARLIMARALIXIBAT CHLORIDESmall mol.Feb 2040
  4. LIVMARLIMARALIXIBAT CHLORIDESmall mol.Oct 2043
  5. LIVMARLIMARALIXIBAT CHLORIDESmall mol.Oct 2043
  6. LIVMARLIMARALIXIBAT CHLORIDESmall mol.Oct 2043
  7. LIVMARLIMARALIXIBAT CHLORIDESmall mol.Oct 2043
  8. CHOLBAMCHOLIC ACIDSmall mol.—
  9. CHOLBAMCHOLIC ACIDSmall mol.—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.